[Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis].
In the paper the review of clinical trials with interferon beta and copolimer-1 in the treatment of multiple sclerosis was presented. The effect of interferon beta and copolimer-1 on relapse frequency, disability and MRI activity has been described. The mechanism of action of interferon beta and copolimer-1 in MS was discussed.
Losy
J
J
Zakład Neuroimmunologii Klinicznej Katedry Neurologii AM w Poznaniu.
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000068717:Glatiramer Acetate; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000378:metabolism; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D012008:Recurrence; D013601:T-Lymphocytes / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism
D000276:Adjuvants, Immunologic; D010455:Peptides; D014409:Tumor Necrosis Factor-alpha; D019010:Vascular Cell Adhesion Molecule-1; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D007371:Interferon-gamma